On March 13, 2025, the Federal Circuit decided in Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (No. 2023-2254) how ...

BioCryst Pharmaceuticals sues Hetero with claims of Orladeyo patent infringement. Orladeyo generated $437.7 million in revenue for BioCryst last year. BioCryst seeks court order to prevent FDA ...

Rogaine was approved by the Food and Drug Administration in 1988, the first drug to win the agency’s endorsement for male ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

A generic product cannot enter the market until the originator product’s IP has expired, but the development process can take ...

As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation | ...

Every year, the UK spends an estimated £2.6billion on generic drugs - medicines that are taken by millions of NHS patients ...

The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s (NYSE: PFE) Inlyta, reports The ...

The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...